Group 1 - As of January 4, 2026, a total of 105 companies listed on the Shanghai Stock Exchange have disclosed share repurchase and increase progress announcements, with 98 related to repurchases and 7 to increases [1] - The total repurchase limit disclosed by 70 companies on the main board exceeds 27.8 billion yuan, while 6 companies reported shareholder increases with a total limit exceeding 4 billion yuan [1] - Notable companies such as Kweichow Moutai, Haier Smart Home, and Sany Heavy Industry have reported repurchase amounts exceeding 4.8 billion yuan [1] Group 2 - China Merchants Industry Holdings has repurchased shares worth 8.25 billion yuan as of December 31, 2025, under a plan to repurchase between 749 million yuan and 1.498 billion yuan [2] - Haier Smart Home and Sany Heavy Industry have reported repurchase amounts of 1.08 billion yuan and 1.36 billion yuan, respectively [2] - Seven companies, including Dongfang Electric and Binhu Chemical, have disclosed increases totaling over 1.7 billion yuan, with significant contributions from stakeholders like the Three Gorges Group [2] Group 3 - In 2025, the total amount of new repurchase and increase plans by companies on the Shanghai Stock Exchange exceeded 138 billion yuan, reflecting a strong commitment to market confidence [3] - Kweichow Moutai completed a 6 billion yuan repurchase plan and initiated an additional plan of 1.5 billion to 3 billion yuan in November 2025 [3] - The Wind stock repurchase index rose by 31.31% in 2025, indicating a historical high and reflecting the positive impact of repurchase and increase actions on market sentiment [3]

值得注意的是，传化智联（002010.SZ）以高达256.07%至361.57%的净利润预计增幅，暂列目前"预增 王"。公司预计2025年归母净利润为5.4亿至7亿元。公告显示，业绩大幅增长除因主营业务取得良好增 长外，也受益于转让部分子公司股权确认的投资收益及回购子公司股权提升持股比例等因素。 传统制造业在此轮业绩预告中表现尤为亮眼。钢铁行业方面，首钢股份（000959.SZ）预计2025年归母 净利润为9.2亿元至10.6亿元，同比增长95.29%至125.01%，增速上限在已披露公司中位居前列。公司表 示，业绩增长得益于产品结构优化、高端化发展及"极低成本"管理理念的贯彻。 同样属于钢铁板块的华菱钢铁（000932.SZ）在消化了补缴环保税及滞纳金约6.57亿元的情况下，依然 预计净利润增长27.97%至47.66%。对此，公司解释，主要得益于降本增效以及高端化、绿色化、智能 化、精益化四化转型等工作的开展。 以电子、医药生物为代表的高景气赛道则呈现批量报喜的态势。其中，电子行业的强一股份 （688809.SH）预计净利润增长52.30%至80.18%；医药行业的百奥赛图（688796.SH）则凭借海外 ...

Investment Rating - The report maintains an "Outperform" rating for the industry [7] Core Insights - The pharmaceutical sector experienced a significant rebound in 2025, driven by innovation, and is expected to reach new highs in 2026 [4][17] - The A-share market saw a 12.9% increase year-to-date, while the H-share market surged by 57% [18] - The report emphasizes the importance of tracking macroeconomic conditions and the potential for valuation recovery in the consumer healthcare sector [4][24] Market Review - The CITIC Pharmaceutical Index fell by 2.0% in the week of December 29, 2025, to January 2, 2026, underperforming the CSI 300 Index by 1.4 percentage points [3][32] - Year-to-date, the CITIC Pharmaceutical Index has risen by 12.9%, lagging behind the CSI 300 Index by 4.8 percentage points [32] - The top-performing stocks for the week included Duorui Pharmaceutical (+15.9%) and Mailland (+10.3%) [47] Sector Performance - The report highlights significant sector differentiation, with the medical services sector (including CXO and innovative supply chains) showing the highest growth, exceeding 50% [24] - The quarterly performance showed a strong start in Q1, followed by fluctuations in Q2 and Q4 due to various market catalysts [27] Investment Strategy - The report suggests focusing on innovative drugs, particularly those with revenue and performance exceeding expectations, as well as companies benefiting from technological advancements [5][4] - Specific stocks recommended for January include Kangfang Biotech, WuXi AppTec, and Aidi Pharmaceutical [5][4]

Core Viewpoint - The manufacturing PMI for December 2025 increased by 0.9 points to 50.1, significantly above the seasonal trend, which typically sees a decline of 0.3 points over the past decade [1][5][6]. The main driving force behind this increase is the upward shift in the economic center of high-tech manufacturing [1][5]. Group 1: Manufacturing Sector - The absolute economic performance is led by the pharmaceutical, automotive, textile, and computer communication electronics industries, supported by the upcoming "two new" policies in 2026, which include subsidies for digital and smart products, and vehicle replacement policies [1][9]. - The computer communication electronics sector has maintained a PMI above 52 for five consecutive months, driven by the "AI+" industry trend [1][9]. - Export orders have rebounded, with the textile industry’s export order index rising above 60 and the pharmaceutical industry’s export order index reaching 55 [1][9]. Group 2: Marginal Changes - Industries showing improvement in economic performance include pharmaceuticals, textiles, electrical machinery, petrochemicals, and metal products, with the pharmaceutical sector potentially benefiting from the flu season [2][12]. - The petrochemical industry has stabilized at a low level, with production indicators rising significantly by 15 points, likely due to stabilizing oil prices in late December [2][12]. - The electrical machinery sector's improvement is linked to the continuation of the 2026 "old-for-new" appliance policy and strong demand in the energy storage sector, with the sector's factory price index rising by 4.9 points in December [2][12]. Group 3: Emerging Industries - Emerging industries such as biotechnology, new energy vehicles, and next-generation information technology continue to maintain high levels of economic performance, with biotechnology seeing a 2.7-point increase in its economic index [2][15]. - Among the seven emerging industries, biotechnology has the highest economic performance, while new energy vehicles and next-generation information technology are in the 50-55 range [15]. Group 4: Construction Sector - The construction industry has returned to economic expansion after four months, with the real estate sector showing a slight increase of 0.5 points in its index [3][16]. - The construction activity index for civil engineering rose by 1.2 points, driven by the concentrated release of new policy financial tools and favorable construction conditions in southern regions [3][16]. - The construction PMI increased by 3.2 points to 52.9, marking a return to economic expansion [3][17]. Group 5: Service Sector - The service sector's business activity index rose by 0.2 points to 49.7, with online information technology services and postal services leading the performance [3][22]. - The financial services and capital market services sectors have business activity indices above 60, indicating high economic performance [3][22]. - The accommodation and catering services sector showed the lowest performance, declining in line with weak consumer mobility data [3][22].

海南自贸港药品、医疗器械"零关税"政策明确，在海南博鳌乐城国际医疗旅游先行区内注册登记具有独 立法人资格并经认定的医疗机构、医学教育高等院校、医药类科研院所，进口政策规定范围内的药品、 医疗器械，可享受免征进口关税、进口环节增值税。该政策有效降低医疗机构运营成本，也减轻了患者 就医负担。 【纠错】 【责任编辑:薛涛】 新华社海口1月4日电（记者吴茂辉）海口海关4日发布数据，自2024年12月31日首票业务落地以来，海 南自贸港药品、医疗器械"零关税"政策已平稳运行一周年，截至2025年12月31日，累计进口"零关税"药 械货值约4.6亿元，减免税款约6200万元。 海口海关相关负责人表示，将继续优化监管服务，引导企业用好用足政策，进一步推动药械"零关税"政 策红利释放，助力乐城先行区打造全球优质医疗资源集聚高地。 ...

Core Insights - In the first eleven months of 2025, trade between China and South Korea reached 2.14 trillion yuan, marking a year-on-year growth of 1.6% [1] - The trade of electromechanical products accounted for 1.43 trillion yuan, growing by 5.9% and representing 67% of the total trade volume, an increase of 2.7 percentage points from the previous year [1] Trade Dynamics - China imported 1.2 trillion yuan worth of goods from South Korea and exported 0.94 trillion yuan, with Sino-Korean trade constituting 5.2% of China's overall foreign trade [1] - There is a deepening collaboration in supply chains, with imports of electronic components and computer accessories from South Korea increasing by 9.9% and 7.4% respectively [1] Emerging Cooperation Areas - In the new sectors, imports of medicinal materials and pharmaceuticals from South Korea rose by 8.9% and 3% respectively, while exports of "new three samples" products and medical instruments to South Korea grew by 12.4% and 1.1% [1] Agricultural Trade Expansion - The trade volume of agricultural products between China and South Korea reached 52.19 billion yuan, reflecting a year-on-year increase of 2.1% [1] - Notably, imports of alcoholic beverages and pasta from South Korea, as well as exports of dried and fresh fruits, nuts, and tea to South Korea, saw double-digit growth rates [1]

Group 1 - The short-term performance of A-shares after the New Year is mainly influenced by policies, external events, liquidity, and overseas market trends [1][6] - Since 2010, in 16 years, the Shanghai Composite Index has risen in 11 instances during the 10 trading days before the holiday and has shown similar patterns after the holiday [1][6] - Positive policies and external events are core influencing factors for post-holiday A-share performance, with examples including the resolution of the "fiscal cliff" in the US in January 2013 and the easing of US-China trade tensions in early 2019 [1][6] Group 2 - Current observations suggest that the A-share spring market is ongoing, with potential for a strong but volatile performance post-New Year [1][6] - There is a likelihood of further positive policy implementation after the holiday, including the rollout of guidelines for equipment updates and trade-in policies, as well as local government meetings to stimulate consumption [1][6] Group 3 - External risks post-holiday are expected to be limited, with a high probability of a Federal Reserve rate cut in January and stable US-China relations, although tensions with Japan may persist [2][7] - Liquidity is anticipated to further loosen, with potential for accelerated capital inflow into the stock market [2][7] Group 4 - The economic recovery remains weak, with industrial profits continuing to decline, but there is potential for recovery in certain sectors, particularly in technology and cyclical industries [2][7] - Historical trends indicate that industries driven by upward policies and trends before the holiday are likely to maintain their strength afterward [3][8] Group 5 - Recommendations for post-holiday investment include focusing on technology, certain cyclical sectors, and consumer industries, with specific mention of machinery, military, new energy, media, computing, electronics, telecommunications, and pharmaceuticals [4][9] - Current PEG ratios for growth sectors like power equipment and media are relatively low, indicating potential for investment [4][9]

Group 1 - The report indicates that geopolitical tensions, particularly the U.S. actions in Venezuela, are expected to boost oil and gold prices, while the impact on equity assets is manageable. Attention should be paid to the Federal Reserve chair nomination, liquidity, and the CES conference, with U.S. stocks showing signs of recovery. [4][12][13] - Domestic PMI for December showed a significant rebound, driven by new subsidies, major projects, and proactive real estate policies. The report anticipates a positive start for A-shares, supported by policy initiatives, increased capital inflow, and technological catalysts. [4][18][19] - The report emphasizes a focus on technology and cyclical industries, particularly in sectors like commercial aerospace, robotics, AI, and semiconductors, as well as lithium batteries, non-ferrous metals, and chemicals. [4][20] Group 2 - The report lists the top ten stocks for January, including companies from various sectors such as electronics, automotive, and healthcare, with no specific ranking provided. [5][10] - Semiconductor company SMIC (688981.SH) is highlighted as a leader in integrated circuit manufacturing, with a projected revenue growth from 574.77 billion to 742.45 billion from 2024 to 2026, reflecting its critical role in the industry. [21][22] - Tianfu Communication (300394.SZ) is noted for its strong revenue growth driven by high-speed optical module demand, with a forecasted revenue increase from 57.33 billion to 106.87 billion from 2025 to 2027. [23][26] - New energy company Haopeng Technology (001283.SZ) is focusing on AI applications and has begun mass production of AI-related products, with projected net profits increasing from 2.47 billion to 5.50 billion from 2025 to 2027. [44][46] - Zhongmin Resources (002738.SZ) is expanding its lithium salt production capacity and has significant projects underway, with revenue expectations of 56.91 billion to 97.27 billion from 2024 to 2026. [48][52] - China Aluminum (601600.SH) reported a revenue increase of 13.95% in Q1 2025, with a focus on improving cash flow and reducing debt levels, indicating a strong operational performance. [54][56]

Core Viewpoint - The "zero tariff" policy for drugs and medical devices in Hainan Free Trade Port has been successfully implemented for one week, significantly reducing operational costs for medical institutions and patient burdens [1]. Group 1: Policy Implementation - The "zero tariff" policy has been in effect since December 31, 2024, and has resulted in a tax reduction of approximately 62 million yuan, with a total value of goods benefiting from the policy amounting to about 460 million yuan [1]. - The policy allows registered medical institutions, higher medical education institutions, and medical research institutes in the Boao Lecheng International Medical Tourism Pilot Zone to import specified drugs and medical devices without paying import tariffs, VAT, or consumption tax [1]. Group 2: Operational Support - Haikou Customs has optimized customs clearance processes and conducted in-depth enterprise research to ensure the effective release of policy benefits, aiming to meet the needs of the beneficiaries [1]. - The customs authority will continue to enhance supervision and services, guiding enterprises to fully utilize the policy and further support the Lecheng Pilot Zone in becoming a global hub for high-quality medical resources [1]. Group 3: Policy Context - The "zero tariff" policy for drugs and medical devices is part of a broader tax incentive framework in the Hainan Free Trade Port, which also includes zero tariffs on self-use production equipment, vehicles, yachts, and raw materials [1].

Core Viewpoint - The strategic cooperation between China National Pharmaceutical Group (Sinopharm) and Betta Pharmaceuticals represents a strong alliance between an innovative pharmaceutical company and a supply chain giant, aiming to create a new ecosystem for an efficient pharmaceutical supply chain [1] Group 1: Strategic Cooperation - The signing ceremony for the strategic cooperation between Sinopharm and Betta Pharmaceuticals took place at Betta's headquarters [1] - This partnership is seen as a model of complementary strengths between an innovative drug company and a supply chain leader [1] - Both companies aim to deepen their collaboration and create a synergistic and efficient pharmaceutical supply chain ecosystem [1] Group 2: Company Statements - Sinopharm's Vice President, Hu Ligang, expressed satisfaction with the strategic cooperation, emphasizing the integration of internal resources and optimization of service models to support innovative companies like Betta [1] - Betta Pharmaceuticals' Chairman, Ding Lieming, acknowledged the significant support from Sinopharm in Betta's commercialization process, highlighting the importance of this partnership in enhancing collaborative innovation outcomes [1]